These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 27634384)

  • 1. Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis.
    Novakovic AM; Krekels EH; Munafo A; Ueckert S; Karlsson MO
    AAPS J; 2017 Jan; 19(1):172-179. PubMed ID: 27634384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
    Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
    Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Keller B; Jack D; Vermersch P
    Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B; Guerreiro R; Costa J; Miguel LS
    J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
    [No Abstract]   [Full Text] [Related]  

  • 6. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
    Afolabi D; Albor C; Zalewski L; Altmann DR; Baker D; Schmierer K
    Mult Scler; 2018 Oct; 24(11):1461-1468. PubMed ID: 28817997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cladribine in aggressive forms of multiple sclerosis.
    Martinez-Rodriguez JE; Cadavid D; Wolansky LJ; Pliner L; Cook SD
    Eur J Neurol; 2007 Jun; 14(6):686-9. PubMed ID: 17539951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New hypointense lesions on MRI in relapsing-remitting multiple sclerosis patients.
    Wagner S; Adams H; Sobel DF; Slivka LS; Sipe JC; Romine JS; Koziol JA
    Eur Neurol; 2000; 43(4):194-200. PubMed ID: 10828648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis.
    Piasecka-Stryczyńska K; Kaczyński Ł; Rolka M; Homa M; Staśkiewicz W; Paczwa P; Wójcik R; Kaczor MP; Rejdak K
    Neurol Neurochir Pol; 2022; 56(6):480-489. PubMed ID: 36421066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between sustained disability progression and functional system scores in relapsing-remitting multiple sclerosis: analysis of placebo data from four randomized clinical trials.
    Scott T; Wang P; You X; Mann M; Sperling B
    Neuroepidemiology; 2015; 44(1):16-23. PubMed ID: 25634764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study.
    Brownlee W; Amin A; Ashton L; Herbert A
    Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets.
    Signori A; Ponzano M; Alexandri N; Giovannoni G; Sormani MP
    Eur J Neurol; 2022 Jul; 29(7):2144-2147. PubMed ID: 35258154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
    Gorrod HB; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
    Value Health; 2019 Jul; 22(7):772-776. PubMed ID: 31277823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study.
    Rejdak K; Stelmasiak Z; Grieb P
    Mult Scler Relat Disord; 2019 Jan; 27():117-120. PubMed ID: 30368223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
    Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
    Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
    Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G; Comi G; Cook S; Rammohan K; Rieckmann P; Soelberg Sørensen P; Vermersch P; Chang P; Hamlett A; Musch B; Greenberg SJ;
    N Engl J Med; 2010 Feb; 362(5):416-26. PubMed ID: 20089960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note.
    Wang G; Cutter GR; Cofield SS; Lublin F; Wolinsky JS; Gustafson T; Krieger S; Salter A
    Mult Scler; 2017 Jun; 23(7):982-987. PubMed ID: 27682227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis.
    Achiron A; Barak Y; Rotstein Z
    Mult Scler; 2003 Oct; 9(5):486-91. PubMed ID: 14582775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.